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The purpose of the experiment is to study the poly(D,L-lactide-co-glycolide) (PLGA) microspheres of 
coated in fish vaccine formulations. In this study, we prepared Pseudomonas bacteria widowed raise 
PLGA microspheres vaccine by double emulsion evaporation maltophilia. It was prepared to support 
the completion of the Stenotrophomonas maltophilia oligonucleotide PLGA microspheres vaccine 
through injection as well as oral and immersion in three ways inoculated based on body weight (100 ± 5 
g) of channel catfish, each has five immunization groups, of which three group were different doses of 
the immune group, the other two groups were not coated with S. maltophilia raising vaccination with 
inactivated Aeromonas group and the control group. During the 0, 28 and 56th day, the immunization 
group were processed in same way. Collection of blood and measuring of immune-related indicators at 




 day were carried out. At the 63th day, 0.2 ml of each fish at the concentration 
of 1 × 10
9
 cfu/ml of Stenotrophomonas widow raising a single cell suspension of viable bacteria was 
injected into the Channel catfish. Continuous observation and recording of the results of each group 
shows that the experimental vaccine preparation of PLGA microspheres encapsulation efficiency was 
88.93%, the immunization route vaccine group versus those in saline control group significantly 
enhance the phagocytic activity of white blood cells, serum lysozyme, complement C3, serum protein 
content and antibody IgM levels. Channel catfish immunized by injection were challenged with live S. 
maltophilia, the relative survival rates of group 3 was 9.16% higher than group 5; however group 1 was 
15% lower than group 5 ,group 2 was 1.67%. Another five groups immunized by oral vaccination were 
challenged with S. maltophilia, the relative survival rates of group 1 to group 3 were 43.33, 65 and 75%, 
but group 5 was only 6.68%. Conclusively, injection and oral vaccination of Stenotrophomonas widow 
raising Aeromonas vaccine PLGA microspheres in Channel catfish has a good immune protective effect, 
while the immersion of the protective effect of various immunization groups was not obvious. 
 





In recent years, an acute epidemic and infectious disease 
of Ictalurus punctatus has emerged in many areas in China 
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and archocele (Wang et al., 2006). The sudden infection 
and high mortality rate due to this disease gravely 
threatened the healthy development of aquacultive 
industries of I. punctatus (Geng et al., 2006). There have 
been some reports on similar cases of such disease in 
American since 1988. Durborow and Hanson (1988) isolated  
bacteria such as Aeromonas hydrophila, Pseudomonas 
spp., Aeromonas   sobria  and  Flavobacterium   




columnaris among others from the organs of sick fish. 
They discovered that due to certain reasons, there was 
decrease in blood flow of the intestine leading to the 
damage of mucosa and subsequently causing such 
phenomenon like intestinal autolysis with protein 
enzymes taking place and intestine rupcture, as well as 
irregular contraction and fold. There has been no 
evidence to support the inference about the connection 
between these isolated bacteria and the disease. Wang 
et al., (2006b) and Geng and Wang (2005) isolated the 
same high pathogenic Stenotrophomonas maltophilia 
from different areas whereby the I. punctatus had been 
infected with intus-susception. Artificial recurrent infection 
experiments show similar clinical symptoms and 
pathological features compared to natural infection, so 
the S. maltophilia was proved to be the pathogen of I. 
punctatus’ intus-susception.  
S. maltophilia is gram-negative bacterium, which 
belongs to unfermentation type, aerobic and not forming 
spores. It covers extensively various water sources, soil 
and plant roots system and is an important source of 
human and infectious bacteria in hospital. This bacterium 
can cause sepsis, infective endocarditis, pneumonia, 
conjunctivitis, encephalitis, urinary tract, gastrointestinal 
tract infection and wound infection, etc. S. maltophilia 
could be infectious not only to human but also to 
terrestrial animal like goats (Johnson, 2003) and pigs 
(Zhang and Xie, 2004) and also to some aquatic animals. 
Ben (2002) reported that S. maltophilia was a type of 
critical pathogens of tunain Europe and USA. Meanwhile, 
this pathogens could also infect aquatic animal like 
crocodile (Harris, 2001), Cuora flavomarginata (Huang 
and Chen, 2002), Trachinotus ovatus (Zhou and Zhu, 
2001) and Eriocheir sinensis (Li and Jiang 2004). S. 
maltophilia showed multiple resistance (Hugh, 1961; Qian 
et al. 2003) to antibiotics owing to its secretion of β-
lactamase and aminoglycoside modifying enzymes. This 
brought tremendous problems to drug treatment of I. 
punctatus’s intussusception resulting from S. maltophilia. 
For example, the residue of antibiotics has led to the 
prohibition of export of I. punctatus from China to 
Alabama (U.S state) (Liu et al., 1999). So, it was urgent 
and necessary to adopt vaccination technology to prevent 
such infection. We chose bacillary antigen of S. 
maltophilia from Ictalurus punctatus to prepare its relevant 
poly(D,L-lactide-co-glycolide) (PLGA) microsphere-
encapsulated-encapsulated vaccine. At the same time, 
we conducted research such as vaccine immunity 
dosage, immune routes and immunity protective effect on 
healthy I. punctatus to develop a new vaccine for aqua-
cultive industries which could effectively prevent I. 
punctatus from S. maltophilia. 
 
 









own laboratory. Healthy I. punctatus, average weight 100 ± 5 g, 
were obtained from the Meishan I. punctatus Farm. 
 
 
The preparation of antigens 
 
S. maltophilia was inoculated to tryptone soy broth (TSB) under 
aseptic condition, cultured under shaking at 28°C，120 r/min for 24 
h. Then, the suspension of cultured bacteria was inactivated by 
0.3% formaldehyde; staved by ultrasonics (300W 10 min), and 
conserved under chill storage at 4°C.  
 
 
The preparation of S. maltophilia PLGA microsphere-
encapsulated vaccine 
 
Production of S. maltophilia PLGA microsphere-encapsulated 
vaccine 
 
Biodegradable polymer, PLGA, prepared using the vaccine as a 
carrier to make S. maltophilia, inactivated bacteria vaccine into 
microspheres vaccine. Using copolymer materials, PLGA (50:50), 
and adopting the water in oil, oil in water (W/O/W) solvent evapo-
ration approaches, was used to produce microspheres within 10 
μm.; at the package rate, the higher the better (Kim et al., 1999, 
Jeffery and O’Hagan, 1993).  PLGA was dissolved into
 
dichloro-
methane (bought from Chongqing Chemical Factory) to compound 
solution of 6%, adding antigenic solution and emulsifying for 3 to 5 
min by 6500 r/min with high speed homogenizer. In the next step, 
the mixed solution was added into the concentration of 10%, bulk of 
30 ml of the polyving alcohol (PVA bought from SIGMA) solution 
and churn by 1100 r/min, evaporating under ordinary temperature 
for 12 to 18 h and centrifuging to collect the microsphere vaccine, 
then washing with deionized water for three times and freeze-drying 
it with freeze drier and conserving it at -20°C for backup. 
 
 
The measurement of technical index of S. maltophilia PLGA 
microsphere-encapsulated vaccine 
 
Electric mirror observation and particle diameter measurement 
 
Under solution situation, PLGA microsphere was transferred onto 
the slide glass and put under microscope (NIKON) to observe the 
outlook of particles. This allows easy measurement and observation 
of the diameter of the dried PLGA microspheres. 
 
 
Encapsulation efficiency measurement  
 
20 mg PLGA microsphere vaccine was dissolved with 0.5 ml, 0.1 
mol/l NaOH and 5% SDS solution. It was vibrated at 37°C for 24 h, 
centrifuged at 12000 r/min and the supernatant collected. BCA 
protein content test kit was used to measure the amount of antigen 
in liquid supernatant（W 包）and the amount of antigen that was 
added when producing microspheres. The encapsulation efficiency 
was counted using the formula below 
 
%100/% TEw WWQ  
 
Immune experiment  
 
The immune experiment could be divided into three immune routes, 
with 5 groups each. Group I, II and III were S. maltophilia PLGA 
microsphere-encapsulated vaccine with different immune dose. 
Group IV was physiological saline solution control group,  Group V  
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Table 1. Changes of phagocytic activity of leucocytes of Ictalurus punctatus in each group. 
 
Group Phagocytic activity of leucocytes of different days 
 0 day 7 days 21 days 35 days 49 days 
Injection immunity 
Group I 0.248 ± 0.007 0.308 ± 0.010
 A
 0.364 ± 0.031
 A
 0.400 ± 0.006
 A
 0.382 ± 0.005
 A
 
Group II 0.254 ±0 .025 0.337 ± 0.018
 B
 0.421 ± 0.019
 B
 0.494 ± 0.011
 C
 0.515 ± 0.010
 C
 
Group III 0.239 ± 0.016 0.382 ± 0.020
 Cd
 0.492 ± 0.008
 C
 0.579 ± 0.029
 D
 0.608 ± 0.023
 D
 
Group IV 0.253 ± 0.046 0.258 ± 0.019 0.261 ± 0.003 0.251 ± 0.004 0.252 ± 0.006 
Group V 0.252 ± 0.010 0.369 ± 0.013
BC
 0.425 ± 0.009
 B
 0.462 ± 0.004 
B




Group I 0.253 ± 0.015 0.299 ± 0.004
 B
 0.358 ± 0.012
 B
 0.397 ± 0.045
 B
 0.364 ± 0.026
 B
 
Group II 0.244 ± 0.008 0.333 ± 0.019
 Bc
 0.410 ± 0.006
 C
 0.465 ± 0.013
 C
 0.492 ± 0.017
 C
 
Group III 0.250 ± 0.012 0.365 ± 0.005
 Cd
 0.453 ± 0.023
 D
 0.526 ± 0.003
 D
 0.577 ± 0.002
 D
 
Group IV 0.251 ± 0.003 0.245 ± 0.051 0.252 ± 0.013 0.259 ± 0.007 0.249 ± 0.022 
Group V 0.257 ± 0.009 0.268 ± 0.007
 a
 0.298 ± 0.006
 A
 0.324 ± 0.004
 A




Group I 0.256 ± 0.005 0.270 ± 0.007
 a
 0.278 ± 0.008
 a
 0.281 ± 0.015
 a
 0.254 ± 0.003 
Group II 0.259 ± 0.017 0.265 ± 0.016
 a
 0.272 ± 0.004
 a
 0.271 ± 0.002
 a
 0.253 ± 0.027 
Group III 0.257 ± 0.022 0.275 ± 0.019
 a
 0.273 ± 0.011
 a
 0.278 ± 0.028
 a
 0.255 ± 0.049 
Group IV 0.252 ± 0.003 0.255 ± 0.003 0.253 ± 0.007 0.25 ± 0.013 0.252 ± 0.005 
Group V 0.252 ± 0.009 0.288 ± 0.003
 a
 0.300 ± 0.018
 a
 0.309 ± 0.017
 a




Different capital letter superscripts in the same column donate extremely significant difference（P<0.01; different small letter 




was non-coated S. maltophilia inactivated vaccine after ultrasonic 




Immunity and blood collection 
 
Feeding of I. punctatus was stopped 12 h before vaccination and 
then anaesthetize with 1% V/V ether. On the first day, different 
groups of I. punctatus was inoculated with PLGA microsphere-
encapsulated vaccine by the way of injection, immersion and oral 
immunity; the immune dose is shown in Table 1. On the 14 and 
28th days, the same dose was separately taken twice to strengthen 
immunity. 5 tails were randomly chosen from each group separately 
on the 1st, 14th, 28th and 42th days to take blood sample on tail 
vein for standby. The samples were divided into two parts: one was 
heparinized anticoagulant for the detection of the phagocytic activity 
of leucocytes and the sterilization activity of phagocyte; the other 
one was non-anticoagulant for the measurement of serum 
lysozyme, complement C3, content of protein and antibody IgM. 
 
 
Measurement of phagocytic activity of leucocytes in blood 
 
The production of leucocytes suspension  
 
To begin, 1.0 ml anticoagulant was added to Ficoll-Hypaque (SG = 
1.070), centrifuged at 2500 r/min for 15 min, the leucocytic stratum 
was picked and suspended with Hank’s and counting, then, the cell 
concentration was adjusted to 1.0 × 10
7 





Measurement of phagocytic activity of leucocytes in blood 
leucocytes  
 
Suspension of 0.5 ml and addition of 0.1 ml 0.4% trypan blue  was  
done with equal mixing. The number of living and dead cells were 
counted by blood cell counting slab in 3 min and using the 
leucocytes suspension whose living cell number were no less than 
90% to measure phagocytic activity (Situ and Wu 1996). The 
samples were divided into 4 parts, then, 0.5 ml Hank’s and 100 μ 
1.0 x 10
8 
cfu/ml Staphylococcus aureus were added with equal 
mixing. After incubating at 25°C for 15, 45, 75 and 105 min, the 
samples were centrifuged at 2000 r/min (the control group not), 
giving up supernatant liquor. After washing twice, cells were dis-
solved with 1.5 ml, 2%Tween-20 solution and adding 1ml MEM, the 
samples were incubated at 20°C for 16 h, with 90 μl MTT solution in 
each tube. After 15 min, we the OD value was measured and the 
best incubation time selected (Xu, 2005). 
 
 
The measurement of serum lysozyme  
 
Under a certain concentration of tubid bacterial liquid, the 
concentration will decrease and the transmittance will increase 
because lysozyme can hydrolyze mucopolysaccharide on bacterial 
cell wall. According to this phenomenon, the content of serum lyso-
zyme can be estimated by the change of turbidity. This experiment 
adopted the lysozyme test kit (Nanjing Jiancheng the first branch of 
the Biological Engineering Institute).  
 
 
The measurement of complement C3 in serum  
 
Complement C3 as antigen in samples can react with C3 as anti-
body in reagent, and then form a certain kind of immune complex 
with some turbidity which has direct proportion with content of 
complement. Comparing to the standard reagent which was 
handled through the same way, we can calculate content of C3 in 
samples. This experiment adopted the complement C3 test kit 
(Zhejiang Yili Kang Bio-Technology Company Limited).  











The measurement of total amount of serum 
 
It is known that the protein molecules has NH3
+
 perssad which may 
join with the negative ion of Coomassile brilliant blue (CBB) dyestuff 
causing brownish red to turn into blue. According to this theory, the 
total amount of serum can be calculated by measuring the absor-
bance. This experiment adopted the CBB-protein test kit (Nanjing 
Jiancheng the first branch of Biological Engineering Institute). 
 
 
The measurement of immunoglobulin M (IgM) in serum  
 
IgM react with the corresponding specific antibody and form 
immune complex whose turbidity can be measured by transparency 
method because the turbidity has direct proportion with the content 
of IgM in serum. This experiment adopted the IgM test kit (Beijing 
Laibo Bio-Materials Institute).  
 
 
Toxic attack  
 
On the 63th day of the experiment, all groups were infected with S. 
maltophilia. To start, I. punctatus light anaesthesia with 1% (V/V) 
diethyl ether was given and abdominal cavity injection at a dose of 
1 × 10
9 
cfu/ml with suspension of S. maltophilia, 0.2 ml for single 
was carried out. Observation and recording of death rate of every 
groups of I. punctatus was done within 30 days. RPS was 











Statistic analysis  
 
SPSS17.0 software, LSD and DUCAN, were used to carry out 







Measurement of technical index of PLGA 
microsphere-encapsulated vaccine 
 
PLGA microsphere suspension prepared by the way of 
double emulsion evaporation gave a milky white suspen-
sion that was easy to lay. The scanning electron 
micrograph is shown in Figure 1 and the particle size was 
about 2.2 μm. Total weight of protein (WT) in suspension 
with added lipid was 11.20 mg by BCA protein assay kit. 
Weight of dissociated protein in supernatant liquor was 




Measurement of phagocytic activity of leukocytes 
 
Changes of OD values of phagocytic capacity on leuko-
cytes against Staphylococcus aureus during the experi-
ment are shown in Table 2. Interclass variance results 
indicated that injection group (groups I to III) of PLGA 
microsphere-encapsulated vaccine after immunity and 
non-coated S. maltophilia inactivated vaccine injection 
group (group V) could both extremely significantly (P < 
0.01) enhance phagocytic activity of leukocytes compa-
red to physiological saline solution control group (group 
IV). Phagocytic activity of group V was significantly (P < 
0.01) higher than that in group I; Phagocytic activity of 
leukocytes increased successively and significantly in 
PLGA microsphere-encapsulated vaccine injection group 
(group I, II and III). PLGA microsphere-encapsulated 
vaccine oral group (group I to III) could both extremely 
significantly (P < 0.01) enhance phagocytize capability of 
leukocytes in each group. The phagocytize capability of 
non-coated S. maltophilia inactivated vaccine oral group 
(group V) was significantly (P < 0.05) higher than that in 
physiological saline solution control group (group IV) on 
the 7th day, but was still significantly ( P < 0.01) lower 
than that in oral PLGA microsphere-encapsulated vac-
cine group I. The phagocytize capability of oral groups I 
to III increased significantly (P < 0.05) with primary 
immunity and extremely significantly (P < 0.01) with 
intensive immunity, successively. PLGA microsphere-
encapsulated vaccine immersion group (groups I to III) 
and non-coated S. maltophilia inactivated vaccine immer-
sion group (group V) significantly (P < 0.05) enhance 
phagocytic activity of leukocytes, while there was no 
significant difference (P > 0.05) between these two 
groups on the phagocytize capability. 
 
 
Measurement of serum lysozyme level 
 
Changes in the content of lysozyme in serum are shown 
in Table 3. Interclass variance results indicated that 
injection group (groups  I - III)  of  PLGA  microsphere-   




Table 2. Changes of lysozyme in serum of Ictalurus punctatus in each group. 
 
Group 
Lysozyme in serum of Ictalurus punctatus of different days 
0 7 21 35 49 
Injection immunity 
Group I  19.14 ± 0.25 23.45 ± 0.32
A
 26.38 ± 0.08
 A
 28.51 ± 0.13 
A
 25.26 ± 0.39
 A
 
Group II 19.20 ± 0.14 25.28 ± 0.09
 B
 30.46 ± 0.11
 B
 34.87 ± 0.53
 C
 36.34 ± 0.29
 C
 
Group III 19.29 ± 0.36 28.37 ± 0.16
 C
 35.33 ± 0.25
 C
 41.15 ± 0.06
 D
 43.19 ± 0.33
 D
 
Group IV 19.25 ± 0.04 19.36 ± 0.13 19.23 ± 0.25 19.32 ± 0.29 19.48 ± 0.44 
Group V 19.31 ± 0.16 26.91 ± 0.87
 BC
 30.87 ± 0.32
 B
 33.25 ± 0.15
 B




Group I 19.72 ± 0.17 22.36 ± 0.04
 A
 25.11 ± 0.33
B
 27.62 ± 0.12
 B
 24.99 ± 0.04
 A
 
Group II 19.40 ± 0.06 25.18 ± 0.14 
Ab
 29.74 ± 0.45
 C
 32.19 ± 0.35
 C
 33.60 ± 0.55
 B
 
Group III 19.71 ± 0.13 27.02 ± 0.25 
Bc
 32.45 ± 0.02
 D
 36.22 ± 0.26
 D
 38.62 ± 0.07
 C
 
Group IV 19.65 ± 0.30 19.49 ± 0.06 19.59 ± 0.07 19.28 ± 0.18 19.39 ± 0.03 
Group V 19.53 ± 0.23 21.38 ± 0.53 22.65 ± 0.07
 A
 23.86 ± 0.12
 A
 20.66 ± 0.11 
Immersion immunity 
Group I 19.24 ± 0.26 20.62 ± 0.41
 a
 20.96 ± 0.66
 a
 20.72 ± 0.22
 a
 20.17 ± 0.34 
Group II 19.08 ± 0.04 21.19 ± 0.20
 a
 21.66 ± 0.14
 a
 21.65 ± 0.48
 a
 20.75 ± 0.24 
Group III 19.11 ± 0.16 21.25 ± 0.07
 a
 21.46 ± 0.25
 a
 21.21 ± 0.33
 a
 20.77 ± 0.14 
Group IV 19.21 ± 0.19 19.38 ± 0.21 19.32 ± 0.12 19.25 ± 0.13 19.30 ± 0.08 
Group V 19.28 ± 0.03 22.54 ± 0.29
 Ab
 23.89 ± 0.37
 Ab
 24.51 ± 0.90
 Ab




Different capital letter superscripts in the same column donate extremely significant difference (P < 0.01); different small letter superscripts 




Table 3. Changes of C3 in serum of I. punctatus in each group. 
 
Group 
C3 in serum of Ictalurus punctatus of different days 
0 7 21 35 49 
Injection immunity 
Group I  0.115 ± 0.008 0.139 ± 0.006
 A
 0.153 ± 0.003
 A
 0.166 ± 0.006
 A
 0.156 ± 0.007
 A
 
Group II 0.118 ± 0.013 0.148 ± 0.002
 B
 0.174 ± 0.004
 B
 0.193 ± 0.004
 B
 0.202 ± 0.007
 Bc
 
Group III 0.122 ± 0.004 0.161 ± 0.002
 C
 0.192 ± 0.006
 C
 0.215 ± 0.005
 C
 0.234 ± 0.010
 D
 
Group IV 0.113 ± 0.001 0.120 ± 0.008 0.122 ± 0.006 0.121 ± 0.004 0.117 ± 0.005 
Group V 0.114 ± 0.019 0.148 ± 0.009
 BC
 0.163 ± 0.001
 B
 0.174 ± 0.002
 B




Group I 0.113 ± 0.009 0.130 ± 0.002
 a
 0.140 ± 0.002
 Ab
 0.149 ± 0.003
 B
 0.132 ± 0.007
 B
 
Group II 0.115 ± 0.004 0.139 ± 0.005
 Ab
 0.161 ± 0.003
 C
 0.180 ± 0.009
 C
 0.186 ± 0.004
 C
 
Group III 0.114 ± 0.009 0.152 ± 0.004
 Bc
 0.178 ± 0.003
 D
 0.202 ± 0.003
 D
 0.213 ± 0.003
 D
 
Group IV 0.116 ± 0.002 0.121 ± 0.007 0.120 ± 0.002 0.121 ± 0.009 0.121 ± 0.004 
Group V 0.120 ± 0.008 0.126 ± 0.002
 a
 0.135 ± 0.003
 A
 0.138 ± 0.008
 A




Group I 0.114 ± 0.005 0.122 ± 0.002
 a
 0.132 ± 0.008
 a
 0.131 ± 0.009
 a
 0.120 ± 0.011 
Group II 0.115 ± 0.003 0.125 ± 0.001
 a
 0.127 ± 0.004
 a
 0.136 ± 0.008
 a
 0.122 ± 0.001 
Group III 0.117 ± 0.003 0.127 ± 0.003
 a
 0.130 ± 0.003
 a
 0.135 ± 0.004
 a
 0.122 ± 0.004 
Group IV 0.116 ± 0.006 0.115 ± 0.008 0.112±0.018 0.115 ± 0.003 0.116 ± 0.010 
Group V 0.118 ± 0.004 0.131 ± 0.005
 A
 0.140 ± 0.002
 Ab
 0.147 ± 0.004
 Ab




Different capital letter superscripts in the same column donate extremely significant difference (P<0.01); different small letter superscripts 
donate significant difference (P < 0.05 




Table 4. Changes of total protein in serum of Ictalurus punctatus in each group. 
 
Groups 
Total protein in serum of Ictalurus punctatus of different days 
0 7 21 35 49 
Injection immunity      
Group I 39.07 ± 0.21 44.15 ± 0.76
 A
 46.64 ± 0.37
 A
 48.22 ± 0.05
 A
 46.20 ± 0.65
 A
 
Group II 40.56 ± 0.29 46.16 ± 0.18
 B
 49.88 ± 0.79
 B
 52.83 ± 0.24
 B
 53.99 ± 0.29
 B
 
Group III 39.82 ± 0.87 48.32 ± 0.13
 C
 53.49 ± 0.52
 C
 57.08 ± 0.28
 C
 59.46 ± 0.25
 C
 
Group IV 40.37 ± 2.02 40.38 ± 2.20 41.18 ± 1.40 41.47 ± 0.76 40.36 ± 1.07 
Group V 40.46 ± 1.18 47.50 ± 0.44
 BC
 49.58 ± 0.80
 B
 51.26 ± 1.00
 B




Group I 39.73 ± 0.88 43.21 ± 0.33
 A
 45.98 ± 0.52
 B
 47.08 ± 0.72
 B
 45.34 ± 1.19
 A
 
Group II 40.00 ± 1.27 45.58 ± 0.49
 Ab
 48.83 ± 0.60
 C
 51.63 ± 0.70
 C
 53.45 ± 0.43
 B
 
Group III 38.95 ± 1.60 47.17 ± 0.45
 Bc
 52.75 ± 0.69
 D
 56.11 ± 0.41
 D
 58.83 ± 0.04
 C
 
Group IV 40.09 ± 1.26 40.22 ± 0.15 40.83 ± 0.81 41.03 ± 1.29 39.98 ± 0.43 
Group V 40.99 ± 0.61 42.07 ± 0.31
 A
 43.29 ± 0.46
 A
 43.85 ± 0.29
 A
 41.58 ± 0.63 
Immersion immunity 
Group I 39.45 ± 0.72 41.54 ± 1.28
 a
 41.36 ± 1.20
 a
 41.61 ± 0.76
 a
 39.19 ± 2.70 
Group II 39.64 ± 1.63 42.15 ± 1.75
 a
 42.60 ± 1.17
 a
 41.71 ± 1.20
 a
 41.60 ± 1.74
 a
 
Group III 39.95 ± 1.62 42.34 ± 0.83
 a
 42.29 ± 0.27
 a
 42.48 ± 0.08
 a
 41.02 ± 2.03 
Group IV 40.60 ± 0.17 40.11 ± 2.41 39.97 ± 1.26 39.74 ± 2.80 40.19  ± 1.52 
Group V 40.12 ± 0.10 43.57 ± 0.34
 Ab
 45.26 ± 0.58
 B
 45.97 ± 0.60 
B




Different capital letter superscripts in the same column donate extremely significant difference (P < 0.01); different small letter 




encapsulated vaccine after immunity and non-coated S. 
maltophilia inactivated vaccine injection group (group V) 
extremely significantly (P < 0.01) enhanced the level of 
lysozyme in serum compared to physiological saline 
solution control group (group IV). The level of lysozyme in 
serum of group V was significant (P < 0.01) higher than 
that in group I and was significantly lower after intensive 
immunity compared to group III; compared to group II, 
there was no significant difference (P > 0.05) on the 7th 
and the 21th days but was significantly lower on the 35th 
and the 49th days. PLGA microspheres-encapsulated 
vaccine oral group (groups I to III) significantly enhanced 
the level of serum lysozyme of each group. Compared to 
group IV, serum lysozyme content of group V showed no 
significant difference on the 7th day and it increased 
significantly on the 21th and the 35th days but decreased 
to such an extent close to the control group IV on the 
49th day; serum lysozyme content of group V was signifi-
cant lower than that in group I; PLGA microspheres-
encapsulated vaccine immersion group (groups I to III) 
and non-coated S. maltophilia inactivated vaccine immer-
sion group (group V) significantly enhance the level of 
serum lysozyme content; serum lysozyme content of 
group V was significantly higher than that in group I to III.   
Measurement of complement C3 in serum 
 
Changes of content of complement C3 in serum are 
shown in Table 4. Interclass variance results indicated 
that injection group (group I to III ) of PLGA microsphere-
encapsulated vaccine after immunity and non-coated S. 
maltophilia inactivated vaccine injection group ( group V) 
significantly (P < 0.01) enhance the level of complement 
C3 in serum compared to physiological saline solution 
control group (group IV) . Content of serum complement 
C3 in group V was significantly (P < 0.01) higher than that 
in group I and was significantly lower after intensive 
immunity compared to group III. Oral group (group I to III) 
of PLGA microsphere-encapsulated vaccine could signifi-
cantly enhance the level of complement C3. Compared to 
group IV, the level of serum complement C3 in group V 
showed significant difference on the 7th day and then 
increased significantly on the 21st and the 35th days; 
decreased on the 49th day but was still above that in 
group IV. Throughout the whole immune process, the 
level of complement C3 in group V was significant on the 
21st day and 35
th
 days being lower on the 49th day than 
that in group I. Immersion group of PLGA microsphere-
encapsulated vaccine   (group I to III)   and  immersion  




Table 5. Changes of IgM in serum of Ictalurus punctatus in each group. 
 
Groups 
IgM in serum of Ictalurus punctatus of different days 
0 7 21 35 49 
Injection immunity 
Group I 1.008 ± 0.015 1.146 ± 0.014
 A
 1.298 ± 0.069
 A
 1.422 ± 0.015
 A
 1.334 ± 0.023
 A
 
Group II 0.977 ± 0.018 1.250 ± 0.033
 B
 1.531 ± 0.014
 B
 1.720 ± 0.040
 B
 1.812 ± 0.052
 Bc
 
Group III   0.964 ± 0.030 1.385 ± 0.097
 C
 1.724 ± 0.007
 C
 1.980 ± 0.058
 C
 2.097 ± 0.084
 D
 
Group IV 0.943 ± 0.034 0.979 ± 0.021 0.992 ± 0.027 0.971 ± 0.015 0.976 ± 0.035 
Group V 0.940 ± 0.033 1.311 ± 0.022
 BC
 1.481 ± 0.012
 B
 1.644 ± 0.018
 B




Group I 0.962 ± 0.040 1.122 ± 0.006
 A
 1.274 ± 0.009
 Ab
 1.410 ± 0.004
 B
 1.306 ± 0.017
 A
 
Group II 0.946 ± 0.043 1.220 ± 0.004
 Ab
 1.458 ± 0.011
 C
 1.625 ± 0.049
 C
 1.753 ± 0.025 
B
 
Group III 0.989 ± 0.042 1.324 ± 0.046
 Bc
 1.616 ± 0.058
 D
 1.837 ± 0.015
 D
 2.007 ± 0.023
 C
 
Group IV 0.988 ± 0.028 1.003 ± 0.014 0.981 ± 0.064 0.981 ± 0.048 0.929 ± 0.012 
Group V 0.958 ± 0.031 0.987 ± 0.019 1.145 ± 0.020
 A
 1.177 ± 0.005
 A
 1.017 ± 0.008 
Immersion immunity 
Group I 0.966 ± 0.021 1.046 ± 0.007
 a
 1.044 ± 0.020
 a
 1.053 ± 0.036
 a
 0.995 ± 0.040 
Group II 0.955 ± 0.030 1.029 ± 0.019
 a
 1.088 ± 0.027
 a
 1.087 ± 0.010
 a
 1.023 ± 0.025 
Group III 0.960 ± 0.028 1.054 ± 0.042
 a
 1.073 ± 0.014
 a
 1.060 ± 0.072
 a
 1.003 ± 0.026 
Group IV 0.950 ± 0.060 0.963 ± 0.070 0.969 ± 0.020 0.952 ± 0.033 0.949 ± 0.005 
Group V 0.922 ± 0.038 1.102 ± 0.007
 Ab
 1.181 ± 0.042
 B
 1.220 ± 0.056
 B




Different capital letters superscripts in the same column donate extremely significant difference (P < 0.01) different small letter 




group of non-coated S. maltophilia inactivated vaccine (Ⅴ 
group) significantly enhanced the level of serum comple-
ment C3. The content of serum complement C3 in group 
V was significantly higher than that in group I to III on the 
21st and 35th day. 
 
 
Measurement of total protein 
 
Changes in the total protein are shown in Table 5. 
Interclass variance results indicated that injection group 
(group I to III) of PLGA microsphere-encapsulated vac-
cine after immunity and non-coated S. maltophilia 
inactivated vaccine injection group (group V) significantly 
(P < 0.01) enhanced the content of total protein 
compared to physiological saline solution control group 
(group IV). The level of total protein in group V was 
significant higher than that in group I but lower than that 
in group III after intensive immunity with no significant 
difference (P > 0.05) compared to group II. Oral group 
(groups I to III) of PLGA microsphere-encapsulated vac-
cine significantly enhanced the level of total protein. Level 
of total protein in group V was significantly higher than 
that in group IV on the 7th, 21st and the 35th days and to 
the same extent lower than that in groupI after intensive 
immunity. Immersion group of PLGA microsphere-
encapsulated vaccine (group I to III), except that in the 
49th week, showed no significant difference and immer-
sion group of non-coated S. maltophilia inactivated 
vaccine (group V) could extremely significantly enhance 
the level of total protein. The level of total protein in group 
V on the 7th day was significant and on the 21th, the 35th 
and the 49th days were extremely significant higher than 
that in group I to III. 
 
 
Measurement of antibody, IgM 
 
Changes in the level of antibody, IgM, were are shown in 
Table 6. Interclass variance results indicated that inject-
tion group (groupI to III) of PLGA microsphere-encap-
sulated vaccine after immunity and non-coated S. 
maltophilia inactivated vaccine injection group (group V) 
significantly (P < 0.01) enhanced the level of IgM com-
pared to physiological saline solution control group 
(group IV). The level of IgM in group V was significantly 
higher than that in group I but lower than that in group Ⅲ 
after intensive immunity. Oral group (group I to III) of 
PLGA microsphere-encapsulated vaccine significantly 
enhanced the level of IgM in all groups. Content of IgM in 
non-coated S. maltophilia inactivated vaccine oral group 
(group V) on the 7th day showed no significant difference 
and on the 21th and the35th days increased significantly 
compared to control group (group IV). Immersion group 
of PLGA microsphere-encapsulated vaccine (group I to III) 
and immersion group of non-coated S. maltophilia 
inactivated vaccine (group) significantly enhanced the 
level of IgM. The level of IgM in group V was  significant   




Table 6. Protective effects of PLGA microparticles on Ictalunes 
punctatus against S. maltophilia. 
 
Groups Dosage Survival no./Total no. RPS 
Injection immunity 
Group I  50 μg/tail 19.67/40 49.17% 
Group II 100 μg/ tail 26.67/40 66.68% 
Group III 200 μg/ tail 29.33/40 73.33% 
Group IV  0.2 ml/ tail 0/40 0 
Group V  200 μg/ tail 25.66/40 64.17% 
Oral immunity 
Group I 50 μg/ tail 17.33/40 43.33% 
Group II 100 μg/ tail 26/40 65% 
Group III 200 μg/ tail 30/40 75% 
Group IV 1 ml/ tail 0/40 0 
Group V  200 μg/ tail 2.67/40 6.68% 
Immersion immunity 
Group I 50 μg/ ml 0.33/40 0.83% 
Group II 100 μg/ ml 0/40 0 
Group III 200 μg/ ml 1/40 2.5% 
Group IV 0.7% 0/40 0 




after primary immunity and extremely significant after 
intensive immunity higher than that in group I to III. 
 
 
The protective effect of PLGA microsphere-
encapsulated vaccine  
  
After immunizing all groups of I. punctatus for 3 times, 
toxic attack with living S. maltophilia suspension were 
performed by the way of abdominal cavity injection on the 
63th day. 14 days later, the statistics of mortality in each 
group and the relative survival rate were calculated. 
Relative survival rate in injection groupI to III was higher 
by 9.16% compared to group V; GroupI to III of different 
dose with the same route of oral immunity both signifi-
cantly (P < 0.01) enhanced the protective effect on I. 
punctatus compared to group V, indicating that PLGA 
microsphere-encapsulated vaccine could protect antigen 
from gastrointestinal damage and promote the immune 
protective effect on I. punctatus effectively. Groups I to III 
of different dose with the same route of immersion 
immunity showed no significant difference (P > 0.05) on 
the protective effect compared to group IV while they 
were significantly lower than that in group V. After expo-
sing group IV to toxic attack, dead fish showed typical 
symptoms of surface congestion, body-color fades, abdo-
minal swelling, ascites and intussusception. Some I. 
punctatus got infected and became sick in each immune 
groups due to the immunity protective failure occurring at 










Effect of S. maltophilia vaccine on leucocytes 
phagocytic activity of I. punctatus 
 
Fishes are lower vertebrates and their specific immunity 
mechanism is not perfect, so non-specific immunity is 
paramount to them (Qian et al., 2003). Leucocytes such 
as granulocyte, monocyte and lymphocyte that also 
belong to phagocyte of osteichthyes and their compo-
sition of mononuclear phagocyte system are the impor-
tant defense system and with that, fish can capture 
antigen and remove pathogenic microorganism (Liu et al., 
1999). Phagocyte of animals can engulf eye winker in 
body and keep information of antigen and pass it to the 
relevant lymphocyte at the same time for digesting the 
pathogenic microorganism and subsequently stimulating 
humoral and cellular immunity. Therefore, measurement 
of phagocytic activity of leucocytes of fish can be used to 
judge the immune status of tested fish. This experiment 
detected the phagocytic activity of leucocytes of two 
groups (test and control groups) of I. punctatus. The test 
group was inoculated with vaccine such as S. maltophilia 
PLGA microsphere-encapsulated vaccine, non-coated S. 
maltophilia inactivated vaccine after ultrasonic disruption 
and liposome vaccine via the following immune routes: 
injection, immersion and oral method. It turned out that 
inoculating farmed fish againt S. maltophilia could 
effectively increase their phagocytic activity of leucocytes. 
We also found that I. punctatus acquired a significant 
humoral immune response in our later determination of 
immune index. Clem et al. (1995) reported that we could 
isolate phagocyte from blood or varieties of immune 
organs and with inactivated S. aureus bacteria body co-
incubation period of time, then smeared and observe the 
situation of phagocyte against bacteria body to determine 
phagocytic activity of fish. Method for detecting 
phagocytic activity of fish needs a heavy workload to 
observe and count the phagocyte although it has advan-
tages like user-friendly control, less demanding on 
experimental conditions, etc. This experiment adopted 
methylthiazoletetrazolium (MTT) staining technique which 
is user-friendly control and repeatable to detect 
phagocytic function of leukocytes and it has been proven 
to be a better test method of phagocytic function of fish 
(Xu, 2005).  
 
 
Effect of S. maltophilia vaccine on serum lysozyme 
activity  
 
Lysozyme is hydrolase specialized in cell wall of microbe 
and is an important part of non-specific immune system 





glycan chain between N-acetylmuramic acid and N-acetyl 
glucosamine of cell wall in Gram-positive bacteria, so that 
cell wall lose toughness and bacteria schizolysis occur 
and subsequently bacteria are destroyed. As gram-
negative bacteria, lysozyme mainly play a role right after 
the complement and other enzymes have destroyed the 
outer bacterial cell wall and the exposure of inner cells 
peptidoglycan (Yang and Zuo, 1993, ChenTerutoyo and 
Alexandra, 1996). In addition to direct sterilization, lyso-
zyme can enhance bacteriolysis which is complement-
mediated. Meanwhile, it also has damaging effects on 
fungi, parasites and viruses (Wang et al., 2000). 
Therefore, lysozyme is of great important for fish to resist 
various kinds of pathogen, especially in the high-density 
culture environment, and plays a crucial role in enhancing 
resistance to disease in fish. Activity of lysozyme in 
serum of fish can rise due to the contact between body 
and antigenic substances or the immunologic stimulant. 
Siwiki et al. (1987) used Pseudomonasalcaligenes and 
Actinodiscus punctata to infect carp and measurement 
showed that the activity of lysozyme markedly improved 
(Siwicki and Studnicka, 1987). It has been found that 
lysozyme exists universally in serum of fish and is the 
material foundation of phagocyte to decide whether the 
phagocyte kills pathogenic bacteria and subsequently 
undermine and eliminate variety of pathogenic micro-
organisms that invade the body to achieve body's 
defense function. Therefore, measurement of lysozyme 
activity of fish can to some extent reflect the immune 
status of non-specific humoral immune response of fish 
(Jorgensen et al., 1993). In this experiment, we confirmed 
that vaccinating farmed fish could effectively improve the 
level of serum lysozyme.  
 
 
The effect of S. maltophilia vaccine on content of 
serum complement 
 
Complements are a group of globulin existing in animal 
organism, which are related to immunity and with enzy-
matic activity and self-regulation and are mainly 
synthesized from liver cells and macrophagocytes. 
Complement in serum mainly come from liver cells and in 
the area with inflammation, from macrophagocytes. Cur-
rently, it has been found that aquatic vertebrates like 
Anguilla japonica, carp, ayu, I. punctatus and Tilapia 
mossambica among others possess complement 
activation route which is similar to that in mammal. The 
route is divided into classical and bypass activation (Cao, 
2006). Complements have no specificity and their activi-
ties are unsteady. But they have effects on bacteriolyzing, 
inactivating virus, dissolving cells, immune adhesion, 
regulating phagocyte and chemotoxis, which play an 
important role in maintaining the body’s own stability and 
anti-infections immunity (Gong, 1999). Among 
components of complement, content of C3 is the highest. 
C3 is the hinge between the classical and  the   bypass  




activation route of complement and also is the medium to 
connect antibody with phagocytes. It can enhance the 
specific immunity mediated by humors and cells and is 
the key component of the compliment system in fish 
(Manning et al., 1994; Sakai, 1992). So C3 is very 
important to fish. The result of this experiment showed 
that vaccinating S. maltophilia vaccine on farmed fish 
could effectively promote complement C3. 
 
 
The effect of S. maltophilia vaccine on content of 
serum protein 
 
Changes of composition and content of serum protein in 
fish have a close relationship with fish’s health, nutrition 
and disease conditions, which can reflect the pathological 
status of body and immune function. When fish are 
hungry or sick, the protein content decreased significantly. 
The elevated levels of serum protein may be affected by 
activation of the body's metabolism and the synthesis 
system. According to the report, oyster infected by 
Perkinsus marinus and clam infected by P. atlanticus 
both showed consistency of increased serum protein. 
This phenomenon may due to the fact that the body was 
irritated resulting from the humoral response and sub-
sequently, synthesized the specific polypeptides. Liu et al. 
(1999) reported that elevated level of serum protein could 
make the level of humoral factors like lysozyme sub-
stances and sterilization substances in serum increased, 
thereby enhancing the body's own disease resistance 
ability (Liu et al., 1999). The result of this experiment 
confirmed that vaccinating S. maltophilia vaccine on 
farmed fish could effectively increase the content of 
humoral factors like lysozyme substances and steriliza-
tion substances in serum of I. punctatus and then 
increased the content of serum protein and subsequently 
enhanced resistance to disease in fish. 
 
 
Effect of S. maltophilia vaccine on content of IgM 
 
Fishes are one of the animals which produced immune 
globulin earliest. From the perspective of system evolu-
tion, the lower the status animals, the fewer types of 
immune globulin they produce. The studies have shown 
that the main types of immune globulin in fish are similar 
to the IgM in mammal in these following aspects: 
secondary structure, electrophoretic mobility, molecular 
weight, heavy (H) and (light) L chain of molecular weight 
and the molecular weight of H, L chain and function; and 
their share of the relative level of serum total protein 
amount is higher than that in mammal (Kobayashi and 
Tomonaga, 2000). This study found that changes in 
trends of globulin are consistent with immune globulin. 
The results showed that the level of serum IgM was the 
highest at 200 μg/tail in group PLGA microsphere-encap-
sulated vaccine with injection immune route. Content  of  




serum IgM in group PLGA microsphere-encapsulated 
vaccine with oral immune route was higher than that in 
the group non-coated S. maltophilia inactivated vaccine, 
indicating PLGA organism biodegradable polyester to 
protect antigen from gastrointestinal enzymes and the 
acidic environment (Mestecky et al., 1994). Li et al., 
(2006) did tracer research on PLGA practically wrapped 
with model protein and it showed that fish disease 
vaccine with PLGA as its carrier could effectively be 
absorbed through the intestinal tract. It has been found 
that in this experiment, the level of serum IgM showed 
significant difference (P < 0.01) when PLGA microsphere-
encapsulated vaccine' dose at 100 μg / tail and 200 μg / 
tail was administere. The level of serum IgM in group 
PLGA microsphere-encapsulated vaccine with immersion 
immune route was lower than that in the group non-
coated S. maltophilia inactivated vaccine with immersion 
immune route. We found that PLGA partially settled down 
soon after being suspended in water which may be the 
reason for poor immune effects. Rombout, (1993) found 
that oral vaccine could increase the level of immune 
globulin (Ig) in intestinal mucus and four times higher 
than that in serum. Injection vaccine could make content 
of Ig in serum higher than that in mucus. Immersion 
method could significantly increase the mucus in skin 
(Rombout, 1993). 
Immersion immunity in this study had bad effect 
compared to the use of injection and oral, which might be 
because the fish has its own mucosal immune system. 
Lobb, (1987)'s research is in line with the above. He used 
soluble antigen like dinitrophenyl-oriented horse serum 
albumin to give immune immersion to I. punctatus and 
then found that it could produce specific mucus antibody 
response, while IgM in serum could not easily be 
transferred to the skin mucus through the vessel, which 
suggested that IgM in fish's mucus might be produced 
locally rather than transferred from the serum (Lobb, 
1987). More and more researches have shown that there 
may exist local mucus secretion system in fish 
(Rombabout and den Van, 1989). 
 
 
Toxic attack  
 
After being exposed to toxic attack with S. maltophilia, 
the control group showed typical symptoms like ascites 
and intussusception, as same as those natural cases with 
morbidity and mortality rates by 100%. While I. punctatus 
in the injection group got sick and died after immunizing 
with PLGA microsphere-encapsulated vaccine, they spe-
cifically manifested the incidence decreased with the 
immune dose increasing. In a word, morbidity in PLGA 
microsphere-encapsulated vaccine immune group was 
lower than that in non-coated S. maltophilia inactivated 
vaccine group and in physiological saline solution control 
group and its symptoms were not typical. After carrying 
out toxic attack, relative immune protection rates in PLGA 





both significantly(P < 0.01) higher than that in non-coated 
S. maltophilia inactivated vaccine group, which indicated 
PLGA microsphere-encapsulated vaccine could protect 
antigen from the gastrointestinal damage and promote 
the immune protective effect on I. punctatus effectively. 
Immersion route with different dose of PLGA  
microsphere-encapsulated vaccine group in the 
protection effect, showed no significant difference (P > 
0.05), compared to physiological saline solution control 
group, which might be due to PLGA microsphere-
encapsulated vaccine particle with huge quality being 





This work was supported by Program for Changjiang 
Scholars and Innovative Research Team in University 
(No.IRT0848), Science and Technology project of Sic-
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